Page last updated: 2024-08-23

razoxane and Cardiomyopathies

razoxane has been researched along with Cardiomyopathies in 62 studies

Research

Studies (62)

Timeframe	Studies, this research(%)	All Research%
pre-1990	7 (11.29)	18.7374
1990's	25 (40.32)	18.2507
2000's	24 (38.71)	29.6817
2010's	6 (9.68)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Brandt, A; Ebner, A; Ebner, B; Forkmann, M; Hofmann, A; Morawietz, H; Polanski, AK; Steinbronn, N; Strasser, RH; Tausche, AK; Wunderlich, C	1
Bjorkling, F; Grauslund, M; Hasinoff, BB; Jensen, LH; Jensen, PB; Martin, E; Sehested, M; Thougaard, AV; Tjørnelund, J	1
Adamcová, M; Aupperle, H; Geršl, V; Mazurová, Y; Popelová, O; Potáčová, A; Štěrba, M	1
Ahn, HS; Choi, HS; Choi, JY; Kang, HJ; Noh, CI; Park, ES; Shin, HY; Yun, YS	1
Asselin, BL; Athale, U; Barry, EV; Clavell, LA; Cohen, HJ; Colan, SD; Larsen, E; Lipshultz, SE; Lipsitz, SR; Michon, B; Miller, TL; Moghrabi, A; Neuberg, DS; Orav, EJ; Sallan, SE; Samson, Y; Schorin, MA; Scully, RE; Silverman, LB	1
Balis, FM; Ginsberg, JP; Sepe, DM	1
Asselin, BL; Athale, UH; Clavell, LA; Colan, SD; Dahlberg, SE; Henkel, JM; Laverdière, C; Lipshultz, SE; Lipsitz, SR; Michon, B; Miller, TL; Neuberg, DS; Rifai, N; Sallan, SE; Schorin, MA; Scully, RE; Silverman, LB	1
Adamcová, M; Bukac, J; Gersl, V; Hrdina, R; Klimtová, I; Machácková, J; Simůnek, T; Vávrová, J	1
Adamcová, M; Gersl, V; Hrdina, R; Kaplanová, J; Klimtová, I; Mazurová, Y; Pelouch, V; Simůnek, T	1
Guchelaar, HJ; Richel, DJ; Schimmel, KJ; van den Brink, RB	1
Caron, HN; Kremer, LC	1
Asselin, BL; Barr, RD; Clavell, LA; Colan, SD; Dalton, VM; Gelber, RD; Hurwitz, CA; Levy, DE; Lipshultz, SE; Lipsitz, SR; Moghrabi, A; Rifai, N; Sallan, SE; Samson, Y; Schorin, MA; Silverman, LB	1
Fujisaki, G; Inokuchi, C; Murashige, N	1
Pouillart, P	1
Anderson, B	1
Adamcová, M; Gersl, V; Holecková, M; Hrdina, R; Kaplanová, J; Klimtová, I; Simůnek, T; Sterba, M	1
Elbl, L; Hrstkova, H; Michalek, J; Tomaskova, I	1
Silber, JH	1
Chan, WY; Fok, TF; Huang, WZ; Lee, SM; Li, CK; Li, K; Ng, PC; Pong, NH; Sung, RY; To, MY; Wong, YO; Yang, M; Zhao, H	1
Freyer, DR	1
Lipshultz, SE	1
Kik, K; Szmigiero, L	1
Granger, CB	1
Adamcová, M; Čajnáková, H; Gersl, V; Hrbatová, L; Ponka, P; Popelová, O; Potáčová, A; Šimůnek, T; Sterba, M	1
Geist, A; Haberstroh, J; Ketelsen, UP; Lebrecht, D; Setzer, B; Walker, UA	1
Bjelogrlic, SK; Jokanovic, M; Jovic, V; Radic, J; Radulovic, S	1
Chen, Y; Deng, HY; Huang, GY; Li, K; Ng, PC; Pong, NH; Sung, RY; Tu, L; Xiang, P; Zhang, L; Zhao, H	1
Baldini, L; Bartoli Klugmann, F; Benussi, B; Decorti, G; Grill, V; Klugmann, S; Mallardi, F	1
Ferrans, VJ; Herman, EH	5
Carrano, RA; Imondi, AR; Perkins, WE; Schroeder, RL	1
Bartoli Klugmann, F; Decorti, G; Klugmann, S	1
Fischer, VW; LaRose, LS; Wang, GM	1
Nesser, ME; Seifert, CF; Thompson, DF	1
Bagdasarov, IuB; Min'kov, ED; Niu-Tian-de, GB; Odzharova, AA; Shkhvatsabaia, LV; Zaĭtseva, TI	1
Garin, AM; Lichinitser, MR; Min'kov, ED; Nakhalova, TA; Odzharova, AA; Vyshinskaia, GV	1
Ferrans, VJ; Herman, EH; Zhang, J	1
Gershanovich, ML; Moiceenko, VM; Orlova, RV	1
Bast, A; Grimbergen, JA; Kramer, K; van Acker, SA; van der Vijgh, WJ; Voest, EE; Zhang, J	1
Della Torre, P; Hagerman, LM; Imondi, AR; Mazué, G; Pinciroli, G; Podestà, A; Robbins, TL; Sullivan, TM	1
Hellmann, K	1
Clark, JR; Ferrans, VJ; Herman, EH; Zhang, J	1
Sauer, H	1
Dedukh, VM; Kolygin, BA; Punanov, IuA; Safonova, SA	1
Sparano, JA	1
Speyer, J; Wasserheit, C	1
Bast, A; Boven, E; Grimbergen, JA; Kramer, K; Kuiper, K; van Acker, SA; van den Berg, DJ; van der Vijgh, WJ	1
Della Torre, P; Imondi, AR; Mazué, G; Moneta, D; Podestà, A; Sammartini, U	1
Muggia, FM; Speyer, JL	1
Bajgar, J; Cerman, J; Gersl, V; Hrdina, R; Machácková, J; Mazurová, Y; Suba, P	1
Bauer, FK; Burke, BE; Cusack, BJ; Gambliel, H; Olson, RD	1
Bernadic, M; Foltinová, A; Hulín, I; Mladosievicova, B; Petrásová, H	1
Kolygin, BA	1
Agen, C; Bernardini, N; Costa, M; Danesi, R; Del Tacca, M; Della Torre, P	1
Alderton, P; Green, MD; Gross, J; Muggia, FM; Sobol, MM; Speyer, JL	1
Alderton, P; Green, MD; Gross, J	1
Blum, RH; Green, MD; Hochester, H; Kramer, E; Meyers, M; Rey, M; Sanger, J; Speyer, JL; Wernz, JC; Zeleniuch-Jacquotte, A	1
Fischer, VW; Hobart, NH; Wang, GM	1

Reviews

11 review(s) available for razoxane and Cardiomyopathies

Article	Year
Cardiotoxicity of cytotoxic drugs. Cancer treatment reviews, 2004, Volume: 30, Issue:2 Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antioxidants; Biomarkers; Calcium Channels; Cardiomyopathies; Cardiotonic Agents; Chelating Agents; Cisplatin; Cyclophosphamide; Fluorouracil; Heart; Humans; Ifosfamide; Oxidative Stress; Razoxane; Risk Factors; Trastuzumab	2004
Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines. Cancer treatment reviews, 2004, Volume: 30, Issue:7 Topics: Adult; Animals; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathies; Cardiotonic Agents; Child; Heart Failure; Humans; Razoxane	2004
Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients. Pediatric blood & cancer, 2005, Jun-15, Volume: 44, Issue:7 Topics: Anthracyclines; Antibiotics, Antineoplastic; Cardiomyopathies; Cardiovascular Agents; Child; Humans; Neoplasms; Razoxane	2005
Exposure to anthracyclines during childhood causes cardiac injury. Seminars in oncology, 2006, Volume: 33, Issue:3 Suppl 8 Topics: Adolescent; Adult; Anthracyclines; Antineoplastic Agents; Cardiomyopathies; Cardiovascular Agents; Child; Disease Progression; Heart; Heart Failure; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Razoxane; Risk Factors; Survivors	2006
[Dexrazoxane (ICRF-187)--a cardioprotectant and modulator of action of some anticancer drugs]. Postepy higieny i medycyny doswiadczalnej (Online), 2006, Volume: 60 Topics: Anthracyclines; Antibiotics, Antineoplastic; Cardiomyopathies; Cardiovascular Agents; Chelating Agents; Neoplasms; Razoxane	2006
Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity. The Annals of pharmacotherapy, 1994, Volume: 28, Issue:9 Topics: Animals; Cardiomyopathies; Dogs; Doxorubicin; Drug Synergism; Humans; Randomized Controlled Trials as Topic; Rats; Razoxane; Swine; Swine, Miniature	1994
Cardioprotection by dexrazoxane (Cardioxane; ICRF 187): progress in supportive care. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 1996, Volume: 4, Issue:4 Topics: Adult; Antibiotics, Antineoplastic; Cardiomyopathies; Cardiovascular Agents; Child; Child, Preschool; Clinical Trials as Topic; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Male; Neoplasms; Razoxane; Treatment Outcome	1996
Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity. Seminars in oncology, 1998, Volume: 25, Issue:4 Suppl 10 Topics: Animals; Anthracyclines; Antineoplastic Agents; Cardiomyopathies; Cardiovascular Agents; Disease Models, Animal; Dogs; Heart; Mice; Rabbits; Rats; Razoxane; Swine	1998
Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations. Seminars in oncology, 1998, Volume: 25, Issue:4 Suppl 10 Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathies; Cardiovascular Agents; Clinical Trials as Topic; Doxorubicin; Drug Administration Schedule; Humans; Paclitaxel; Razoxane	1998
Strategies for reduction of anthracycline cardiac toxicity. Seminars in oncology, 1998, Volume: 25, Issue:5 Topics: Adult; Animals; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathies; Cardiovascular Agents; Chelating Agents; Child; Clinical Trials as Topic; Diagnostic Imaging; Humans; Liposomes; Razoxane	1998
ICRF-187 (ADR-529) cardioprotection against anthracycline-induced cardiotoxicity: clinical and preclinical studies. Cancer treatment and research, 1991, Volume: 58 Topics: Animals; Antibiotics, Antineoplastic; Cardiomyopathies; Humans; Razoxane; Stereoisomerism	1991

Trials

10 trial(s) available for razoxane and Cardiomyopathies

Article	Year
Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors. Journal of Korean medical science, 2010, Volume: 25, Issue:9 Topics: Adolescent; Antibiotics, Antineoplastic; Cardiomyopathies; Cardiovascular Agents; Child; Child, Preschool; Cohort Studies; Disease-Free Survival; Doxorubicin; Echocardiography; Female; Follow-Up Studies; Heart Failure; Humans; Infant; Male; Neoplasms; Razoxane; Ventricular Function, Left	2010
Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. The Lancet. Oncology, 2010, Volume: 11, Issue:10 Topics: Adolescent; Antibiotics, Antineoplastic; Biomarkers; Canada; Cardiomyopathies; Cardiovascular Agents; Child; Child, Preschool; Disease-Free Survival; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Male; Myocardial Contraction; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Puerto Rico; Razoxane; Risk Assessment; Risk Factors; Survivors; Time Factors; Treatment Outcome; Troponin T; Ultrasonography; United States; Ventricular Function, Left; Young Adult	2010
Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Apr-01, Volume: 30, Issue:10 Topics: Antibiotics, Antineoplastic; Biomarkers; C-Reactive Protein; Cardiomyopathies; Cardiotonic Agents; Child; Child, Preschool; Doxorubicin; Echocardiography; Female; Heart; Humans; Male; Natriuretic Peptide, Brain; Peptide Fragments; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Razoxane; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Troponin T; Ventricular Function, Left; Ventricular Remodeling	2012
The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. The New England journal of medicine, 2004, Jul-08, Volume: 351, Issue:2 Topics: Antibiotics, Antineoplastic; Cardiomyopathies; Cardiovascular Agents; Chelating Agents; Child; Disease-Free Survival; Doxorubicin; Echocardiography; Female; Heart; Humans; Logistic Models; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Razoxane; Troponin T; Ventricular Function, Left	2004
Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2006, Volume: 14, Issue:2 Topics: Adolescent; Adult; Anthracyclines; Antibiotics, Antineoplastic; Cardiomyopathies; Cardiovascular Agents; Child; Child, Preschool; Echocardiography; Female; Follow-Up Studies; Heart Failure; Hematologic Neoplasms; Humans; Male; Razoxane; Retrospective Studies; Stroke Volume; Survival Analysis; Treatment Outcome	2006
[An evaluation of the cardioprotective action of the preparation ICRF-187 (Cardioxane) during the treatment of breast cancer with large doses of adriamycin]. Terapevticheskii arkhiv, 1994, Volume: 66, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiomyopathies; Cardiovascular Agents; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Heart; Humans; Middle Aged; Myocardial Contraction; Razoxane; Time Factors	1994
[Prevention of cardiotoxicity of doxorubicin (Adriamycin) using cardioxane (ICRF-187, dexrazoxane) in the combination chemotherapy of disseminated breast cancer]. Voprosy onkologii, 1993, Volume: 39, Issue:1-3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiomyopathies; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Razoxane; Treatment Outcome; Ventricular Function, Left	1993
Signal-averaged electrocardiography in survivors of Hodgkin's disease treated with and without dexrazoxane. Neoplasma, 2001, Volume: 48, Issue:1 Topics: Adolescent; Antineoplastic Agents; Arrhythmias, Cardiac; Cardiomyopathies; Cardiovascular Agents; Child; Child, Preschool; Combined Modality Therapy; Doxorubicin; Electrocardiography; Female; Fourier Analysis; Hodgkin Disease; Humans; Infant; Male; Razoxane	2001
ICRF-187 (ADR-529) cardioprotection against anthracycline-induced cardiotoxicity: clinical and preclinical studies. Cancer treatment and research, 1991, Volume: 58 Topics: Animals; Antibiotics, Antineoplastic; Cardiomyopathies; Humans; Razoxane; Stereoisomerism	1991
A prospective randomized trial of ICRF-187 for prevention of cumulative doxorubicin-induced cardiac toxicity in women with breast cancer. Cancer treatment reviews, 1990, Volume: 17, Issue:2-3 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiomyopathies; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Heart; Humans; Prospective Studies; Razoxane	1990

Other Studies

42 other study(ies) available for razoxane and Cardiomyopathies

Article	Year
Dexrazoxane prevents the development of the impaired cardiac phenotype in caveolin-1-disrupted mice. Journal of cardiovascular pharmacology, 2013, Volume: 61, Issue:6 Topics: Animals; Apoptosis; Atrial Natriuretic Factor; Cardiomyopathies; Cardiovascular Agents; Caveolin 1; Mice; Mice, Inbred C57BL; Mice, Knockout; Nitric Oxide Synthase; Phenotype; Razoxane; Reactive Oxygen Species; Treatment Outcome; Ventricular Function, Left	2013
Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy. Toxicology, 2009, Jan-08, Volume: 255, Issue:1-2 Topics: Animals; Animals, Newborn; Antibiotics, Antineoplastic; Antineoplastic Agents; Cardiomyopathies; Colony-Forming Units Assay; Crithidia fasciculata; DNA; DNA Topoisomerases, Type II; Doxorubicin; Ferric Compounds; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Mice; Mitochondria, Heart; Myocardium; Myocytes, Cardiac; Rats; Rats, Inbred SHR; Razoxane; Sarcoplasmic Reticulum; Troponin I	2009
Cardiac remodeling and MMPs on the model of chronic daunorubicin-induced cardiomyopathy in rabbits. Physiological research, 2010, Volume: 59, Issue:5 Topics: Animals; Antibiotics, Antineoplastic; Cardiomyopathies; Cardiovascular Agents; Chronic Disease; Collagen; Daunorubicin; Disease Models, Animal; Drug Interactions; Fibrosis; Hydroxyproline; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Myocardium; Rabbits; Razoxane; Ventricular Remodeling	2010
Dexrazoxane as a cardioprotectant in children receiving anthracyclines. The oncologist, 2010, Volume: 15, Issue:11 Topics: Adolescent; Anthracyclines; Antineoplastic Agents; Arrhythmias, Cardiac; Cardiomyopathies; Cardiotonic Agents; Child; Child, Preschool; Heart Failure; Humans; Razoxane; Risk Factors; Treatment Outcome; Young Adult	2010
Troponins in experimental studies. Acta medica (Hradec Kralove), 2002, Volume: 45, Issue:1 Topics: Animals; Antibiotics, Antineoplastic; Biomarkers; Cardiomyopathies; Daunorubicin; Heart; Male; Protective Agents; Rabbits; Razoxane; Troponin T	2002
Protein profiling in daunorubicin-induced cardiomyopathy. General physiology and biophysics, 2003, Volume: 22, Issue:3 Topics: Animals; Antibiotics, Antineoplastic; Cardiomyopathies; Cardiotonic Agents; Daunorubicin; Heart Ventricles; Male; Proteins; Rabbits; Razoxane	2003
Anthracycline cardiotoxicity in children. The New England journal of medicine, 2004, Jul-08, Volume: 351, Issue:2 Topics: Anthracyclines; Cardiomyopathies; Cardiovascular Agents; Chelating Agents; Child; Heart; Humans; Predictive Value of Tests; Razoxane; Risk Factors; Troponin T	2004
Doxorubicin-induced myocardial injury. The New England journal of medicine, 2004, Oct-28, Volume: 351, Issue:18 Topics: Antibiotics, Antineoplastic; Cardiomyopathies; Cardiovascular Agents; Disease-Free Survival; Doxorubicin; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Razoxane; Remission Induction	2004
Myocardial content of selected elements in experimental anthracycline-induced cardiomyopathy in rabbits. Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine, 2005, Volume: 18, Issue:2 Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Calcium; Cardiomyopathies; Disease Models, Animal; Iron; Magnesium; Male; Myocardium; Potassium; Rabbits; Razoxane; Selenium; Trace Elements	2005
Can dexrazoxane reduce myocardial injury in anthracycline-treated children with acute lymphoblastic leukemia? Nature clinical practice. Oncology, 2004, Volume: 1, Issue:1 Topics: Antibiotics, Antineoplastic; Cardiomyopathies; Cardiovascular Agents; Chelating Agents; Child; Clinical Trials as Topic; Disease-Free Survival; Doxorubicin; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Razoxane; Troponin T	2004
Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin. Circulation, 2006, May-09, Volume: 113, Issue:18 Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Blood Cell Count; Cardiomyopathies; Cardiovascular Agents; Cells, Cultured; Doxorubicin; Drug Evaluation, Preclinical; Heart Rate; Male; Mice; Mice, Inbred BALB C; Myoblasts; Myocytes, Cardiac; Proto-Oncogene Proteins c-akt; Rats; Razoxane; Reactive Oxygen Species; Single-Blind Method; Thrombopoietin; Ultrasonography	2006
Measuring the impact of dexrazoxane cardioprotection. Pediatric blood & cancer, 2007, Volume: 48, Issue:4 Topics: Cardiomyopathies; Cardiotonic Agents; Cohort Studies; Doxorubicin; Drug Evaluation; Echocardiography, Stress; Humans; Razoxane; Retrospective Studies; Risk	2007
Prediction and prevention of chemotherapy-induced cardiomyopathy: can it be done? Circulation, 2006, Dec-05, Volume: 114, Issue:23 Topics: Angiotensin-Converting Enzyme Inhibitors; Anthracyclines; Antineoplastic Agents; Cardiomyopathies; Cardiovascular Agents; Dose-Response Relationship, Drug; Heart; Humans; Predictive Value of Tests; Razoxane; Risk Factors; Stroke Volume	2006
Evaluation of ECG time intervals in a rabbit model of anthracycline-induced cardiomyopathy: a useful tool for assessment of cardioprotective agents. Physiological research, 2007, Volume: 56, Issue:2 Topics: Aldehydes; Animals; Cardiomyopathies; Cardiotonic Agents; Chronic Disease; Daunorubicin; Disease Models, Animal; Drug Evaluation, Preclinical; Electrocardiography; Heart Conduction System; Hydrazones; Iron Chelating Agents; Male; Myocardial Contraction; Pyridoxal; Rabbits; Razoxane; Time Factors; Troponin T	2007
Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. British journal of pharmacology, 2007, Volume: 151, Issue:6 Topics: Animals; Antibiotics, Antineoplastic; Cardiomyopathies; Cardiovascular Agents; DNA, Mitochondrial; Doxorubicin; Electron Transport Complex IV; Energy Metabolism; Gene Expression; Male; Malondialdehyde; Mitochondria, Heart; Oxidative Phosphorylation; Rats; Rats, Wistar; Razoxane; Reactive Oxygen Species; Superoxides	2007
Effects of dexrazoxane and amifostine on evolution of Doxorubicin cardiomyopathy in vivo. Experimental biology and medicine (Maywood, N.J.), 2007, Volume: 232, Issue:11 Topics: Amifostine; Animals; Antibiotics, Antineoplastic; Cardiomyopathies; Cardiovascular Agents; Creatine Kinase; Doxorubicin; Female; Hydroxybutyrate Dehydrogenase; Mice; Mice, Inbred BALB C; Myocardium; Radiation-Protective Agents; Razoxane; Time Factors	2007
Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model. Cancer chemotherapy and pharmacology, 2009, Volume: 63, Issue:2 Topics: Animals; Antibiotics, Antineoplastic; Blotting, Western; Body Weight; Cardiomyopathies; Chelating Agents; Doxorubicin; Echocardiography; Extracellular Signal-Regulated MAP Kinases; Male; Microscopy, Electron; Mitochondria, Heart; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Myocardium; Organ Size; Phosphorylation; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Razoxane; Up-Regulation	2009
Effects of ICRF 159 on adriamycin-induced cardiomyopathy in rats. Cancer letters, 1983, Volume: 19, Issue:1 Topics: Animals; Calcium; Cardiomyopathies; Doxorubicin; Edetic Acid; Male; Myocardium; Piperazines; Prognosis; Rats; Rats, Inbred Strains; Razoxane	1983
Influence of vitamin E and ICRF-187 on chronic doxorubicin cardiotoxicity in miniature swine. Laboratory investigation; a journal of technical methods and pathology, 1983, Volume: 49, Issue:1 Topics: Animals; Body Weight; Cardiomyopathies; Doxorubicin; Female; Male; Piperazines; Razoxane; Swine; Swine, Miniature; Vitamin E	1983
Effect of ICRF-187 on doxorubicin-induced myocardial effects in the mouse and guinea pig. British journal of cancer, 1982, Volume: 46, Issue:4 Topics: Animals; Cardiomyopathies; Doxorubicin; Female; Guinea Pigs; Heart Rate; Histamine; Kidney Diseases; Male; Mice; Mice, Inbred ICR; Myocardial Contraction; Piperazines; Razoxane; Stereoisomerism	1982
[Myocardial disease caused by adriamycin. Experimental animal models and possible pharmacologic prevention]. Minerva medica, 1982, May-07, Volume: 73, Issue:19 Topics: Animals; Cardiomyopathies; Carnitine; Disease Models, Animal; Doxorubicin; Mice; Rabbits; Rats; Razoxane; Verapamil	1982
Mitigating effects of ICRF-159 (razoxane) on a daunomycin-induced cardiomyopathy in mice. Drug and chemical toxicology, 1982, Volume: 5, Issue:2 Topics: Animals; Cardiomyopathies; Daunorubicin; Mice; Myocardium; Piperazines; Razoxane	1982
Dexrazoxane for cardiac protection against doxorubicin. The Medical letter on drugs and therapeutics, 1995, Nov-24, Volume: 37, Issue:962 Topics: Cardiomyopathies; Doxorubicin; Drug Administration Schedule; Female; Humans; Randomized Controlled Trials as Topic; Razoxane	1995
[The use of Cardioxan as a cardioprotective agent during antitumor chemotherapy]. Terapevticheskii arkhiv, 1994, Volume: 66, Issue:7 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiomyopathies; Cardiovascular Agents; Cyclophosphamide; Doxorubicin; Drug Evaluation; Drug Interactions; Female; Fluorouracil; Heart; Humans; Middle Aged; Razoxane; Remission Induction	1994
Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats. Cancer chemotherapy and pharmacology, 1994, Volume: 35, Issue:2 Topics: Animals; Blood Pressure; Body Weight; Cardiomyopathies; Deferoxamine; Doxorubicin; Heart Rate; Injections, Intraperitoneal; Injections, Intravenous; Kidney Diseases; Male; Rats; Rats, Inbred SHR; Razoxane	1994
Timing of treatment with ICRF-187 and its effect on chronic doxorubicin cardiotoxicity. Cancer chemotherapy and pharmacology, 1993, Volume: 32, Issue:6 Topics: Animals; Body Weight; Cardiomyopathies; Dogs; Doxorubicin; Female; Male; Razoxane; Time Factors	1993
Doxorubicin-induced cardiotoxicity monitored by ECG in freely moving mice. A new model to test potential protectors. Cancer chemotherapy and pharmacology, 1996, Volume: 38, Issue:1 Topics: Analysis of Variance; Animals; Antineoplastic Agents, Alkylating; Behavior, Animal; Body Weight; Cardiomyopathies; Cardiovascular Agents; Doxorubicin; Drug Interactions; Electrocardiography; Heart; Heart Atria; Heart Rate; Injections, Intraperitoneal; Injections, Intravenous; Male; Mice; Mice, Inbred BALB C; Razoxane; Telemetry	1996
Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs. Cancer research, 1996, Sep-15, Volume: 56, Issue:18 Topics: Animals; Antineoplastic Agents; Cardiomyopathies; Dogs; Dose-Response Relationship, Drug; Doxorubicin; Female; Heart; Humans; Male; Mice; Mice, Inbred ICR; Mice, Inbred Strains; Rats; Rats, Sprague-Dawley; Razoxane	1996
Doxorubicin-induced apoptosis in spontaneously hypertensive rats: differential effects in heart, kidney and intestine, and inhibition by ICRF-187. Journal of molecular and cellular cardiology, 1996, Volume: 28, Issue:9 Topics: Animals; Apoptosis; Cardiomyopathies; Cardiovascular Agents; Dose-Response Relationship, Drug; Doxorubicin; Heart; Hypertension; Immunohistochemistry; Intestines; Iron Chelating Agents; Kidney; Kidney Diseases; Male; Microscopy, Electron; Myocardium; Rats; Rats, Inbred SHR; Razoxane	1996
[The prevention of anthracycline-induced cardiomyopathy with a chelating agent (dexrazoxane = ICRF-187)]. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1997, Volume: 173, Issue:1 Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Cardiomyopathies; Cardiovascular Agents; Chelating Agents; Humans; Randomized Controlled Trials as Topic; Razoxane	1997
[The use of Cardioxane in chemotherapy of malignant neoplasms in children]. Voprosy onkologii, 1997, Volume: 43, Issue:4 Topics: Adolescent; Antibiotics, Antineoplastic; Cardiomyopathies; Cardiovascular Agents; Child; Child, Preschool; Female; Humans; Male; Razoxane; Treatment Outcome	1997
Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin. Clinical cancer research : an official journal of the American Association for Cancer Research, 1997, Volume: 3, Issue:10 Topics: Animals; Antibiotics, Antineoplastic; Antioxidants; Breast Neoplasms; Cardiomyopathies; Catechin; Chelation Therapy; Cystadenocarcinoma, Serous; Dose-Response Relationship, Drug; Doxorubicin; Drug Interactions; Electrocardiography; Female; Flavonoids; Flavonols; Free Radical Scavengers; Free Radicals; Humans; Hydroxyethylrutoside; Iron; Iron Chelating Agents; Kaempferols; Mice; Mice, Nude; Molecular Structure; Neoplasm Transplantation; Ovarian Neoplasms; Quercetin; Razoxane; Rutin; Telemetry; Tumor Cells, Cultured; Weight Loss	1997
Protection against doxorubicin-induced cardiotoxicity in weanling rats by dexrazoxane. Cancer chemotherapy and pharmacology, 1999, Volume: 43, Issue:2 Topics: Aging; Animals; Antineoplastic Agents; Body Weight; Cardiomyopathies; Chelating Agents; Doxorubicin; Erythrocytes; Growth; Leukocytes; Male; Organ Size; Rats; Rats, Sprague-Dawley; Razoxane; Weaning	1999
Doxorubicin-induced cardiomyopathy. The New England journal of medicine, 1999, Feb-25, Volume: 340, Issue:8 Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathies; Cardiovascular Agents; Doxorubicin; Humans; Razoxane	1999
Cholinesterases in dexrazoxane-treated daunorubicin cardiomyopathy in rabbits. General physiology and biophysics, 1999, Volume: 18, Issue:4 Topics: Acetylcholinesterase; Animals; Antibiotics, Antineoplastic; Body Weight; Butyrylcholinesterase; Cardiomyopathies; Cardiovascular Agents; Daunorubicin; Heart; Male; Myocardium; Rabbits; Razoxane; Ventricular Function, Left	1999
Prevention by dexrazoxane of down-regulation of ryanodine receptor gene expression in anthracycline cardiomyopathy in the rat. British journal of pharmacology, 2000, Volume: 131, Issue:1 Topics: Animals; Antibiotics, Antineoplastic; Cardiomyopathies; Daunorubicin; Down-Regulation; Gene Expression Regulation; Glyceraldehyde-3-Phosphate Dehydrogenases; Male; Rats; Rats, Inbred F344; Razoxane; RNA, Messenger; Ryanodine Receptor Calcium Release Channel	2000
[Cardioxan--a drug of prevention of anthracycline-related cardiotoxicity in pediatric oncology]. Voprosy onkologii, 2002, Volume: 48, Issue:1 Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Cardiomyopathies; Cardiovascular Agents; Child; Child, Preschool; Humans; Razoxane	2002
Reducing doxorubicin cardiotoxicity in the rat using deferred treatment with ADR-529. Cancer chemotherapy and pharmacology, 1992, Volume: 30, Issue:2 Topics: Animals; Cardiomyopathies; Doxorubicin; Drug Administration Schedule; Electrocardiography; Female; Heart; Rats; Rats, Inbred Strains; Razoxane; Sodium Chloride; Time Factors	1992
Role of (+-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) in modulating free radical scavenging enzymes in doxorubicin-induced cardiomyopathy. Cancer research, 1990, Aug-15, Volume: 50, Issue:16 Topics: Animals; Cardiomyopathies; Doxorubicin; Female; Free Radicals; Glutathione; Glutathione Peroxidase; Heart; Kidney; Liver; Mice; Mice, Inbred BALB C; Microscopy, Electron; Muscles; Myocardium; Piperazines; Razoxane; Reference Values; Stereoisomerism; Superoxide Dismutase	1990
Examination of the potential long-lasting protective effect of ICRF-187 against anthracycline-induced chronic cardiomyopathy. Cancer treatment reviews, 1990, Volume: 17, Issue:2-3 Topics: Animals; Cardiomyopathies; Chronic Disease; Daunorubicin; Male; Myocardium; Myofibrils; Rabbits; Razoxane; Time Factors; Vacuoles	1990
Mitigation of an anthracycline-induced cardiomyopathy by pretreatment with razoxane: a quantitative morphological assessment. Virchows Archiv. B, Cell pathology including molecular pathology, 1986, Volume: 51, Issue:4 Topics: Animals; Cardiomyopathies; Daunorubicin; Drug Administration Schedule; Intracellular Membranes; Male; Mice; Microscopy, Electron; Mitochondria, Heart; Myocardium; Piperazines; Razoxane; Sarcoplasmic Reticulum; Time Factors	1986
Pretreatment with ICRF-187 provides long-lasting protection against chronic daunorubicin cardiotoxicity in rabbits. Cancer chemotherapy and pharmacology, 1986, Volume: 16, Issue:2 Topics: Animals; Blood Cell Count; Body Weight; Cardiomyopathies; Daunorubicin; Drug Administration Schedule; Drug Interactions; Hemoglobins; Injections, Intraperitoneal; Injections, Intravenous; Male; Piperazines; Rabbits; Razoxane	1986